NO923858L - Inhibitor for aterosklerose-intimalfortykning - Google Patents

Inhibitor for aterosklerose-intimalfortykning

Info

Publication number
NO923858L
NO923858L NO92923858A NO923858A NO923858L NO 923858 L NO923858 L NO 923858L NO 92923858 A NO92923858 A NO 92923858A NO 923858 A NO923858 A NO 923858A NO 923858 L NO923858 L NO 923858L
Authority
NO
Norway
Prior art keywords
alkyl
hydrogen
butoxy
chem
tert
Prior art date
Application number
NO92923858A
Other languages
English (en)
Other versions
NO302452B1 (no
NO923858D0 (no
Inventor
Yasushi Saito
Masaki Kitahara
Mitsuaki Sakashita
Kyomi Toyoda
Toshie Shibazaki
Original Assignee
Nissan Chemical Ind Ltd
Kowa Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nissan Chemical Ind Ltd, Kowa Co filed Critical Nissan Chemical Ind Ltd
Publication of NO923858D0 publication Critical patent/NO923858D0/no
Publication of NO923858L publication Critical patent/NO923858L/no
Publication of NO302452B1 publication Critical patent/NO302452B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Quinoline Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
NO923858A 1991-10-04 1992-10-02 Anvendelse av kondenserte pyridinderivater for fremstilling av farmasöytisk preparat NO302452B1 (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP03257870A JP3130342B2 (ja) 1991-10-04 1991-10-04 動脈硬化性血管内膜肥厚抑制薬

Publications (3)

Publication Number Publication Date
NO923858D0 NO923858D0 (no) 1992-10-02
NO923858L true NO923858L (no) 1993-04-05
NO302452B1 NO302452B1 (no) 1998-03-09

Family

ID=17312323

Family Applications (1)

Application Number Title Priority Date Filing Date
NO923858A NO302452B1 (no) 1991-10-04 1992-10-02 Anvendelse av kondenserte pyridinderivater for fremstilling av farmasöytisk preparat

Country Status (18)

Country Link
US (1) US6162798A (no)
EP (1) EP0535548B1 (no)
JP (1) JP3130342B2 (no)
KR (1) KR100264543B1 (no)
AT (1) ATE209035T1 (no)
AU (1) AU652669B2 (no)
CA (1) CA2079706C (no)
CZ (1) CZ281786B6 (no)
DE (1) DE69232217T2 (no)
DK (1) DK0535548T3 (no)
HU (1) HU214624B (no)
MX (1) MX9205659A (no)
NO (1) NO302452B1 (no)
NZ (1) NZ244555A (no)
RU (1) RU2114620C1 (no)
SK (1) SK279277B6 (no)
TW (1) TW238300B (no)
UA (1) UA39095C2 (no)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995011898A1 (en) * 1992-05-12 1995-05-04 Nissan Chemical Industries Ltd. Condensed pyridine type mevalonolactone intermediate and process for its production
ES2201266T3 (es) * 1996-01-17 2004-03-16 Taiho Pharmaceutical Company Limited Inhibidores del espesamiento de la capa intima.
NZ509401A (en) * 1998-07-23 2002-08-28 Nissan Chemical Ind Ltd Process for the preparation of quinoline derivative using the intermediate 2-cyclopropyl-3-(3-cyano-prop-2-ene)-4-(4-fluorophenyl)-quinoline
WO2000042016A1 (fr) * 1999-01-14 2000-07-20 Nissan Chemical Industries, Ltd. Fabrication de quinlinecarbaldéhyde
JP4496586B2 (ja) * 2000-01-24 2010-07-07 日産化学工業株式会社 キノリルアクリロニトリルの製造法及びその中間体
EP1251124B1 (en) * 2000-01-24 2007-07-04 Nissan Chemical Industries, Ltd. Process for the preparation of quinolylpropenal
JP4496585B2 (ja) * 2000-01-24 2010-07-07 日産化学工業株式会社 キノリルプロペナールの製造方法
JP4496584B2 (ja) * 2000-01-24 2010-07-07 日産化学工業株式会社 キノリルプロペナールの製造法
JP4867071B2 (ja) * 2000-02-21 2012-02-01 日産化学工業株式会社 キノリン誘導体の製造方法
US6855824B2 (en) 2000-02-21 2005-02-15 Kuraray Co., Ltd. Processes for preparing quinoline derivatives and intermediates thereof
AU2001264313A1 (en) * 2000-06-20 2002-01-02 Japan Tobacco Inc. Pyrazolopyridine compounds and use thereof as drugs
AU2003213682C1 (en) * 2002-03-04 2008-06-12 Medimmune, Inc. Methods of preventing or treating disorders by administering an integrin alphavbeta3 antagonist in combination with an HMG-CoA reductase inhibitor or a bisphosphonate
EP1568693A4 (en) * 2002-11-06 2007-09-05 Nissan Chemical Ind Ltd PROCESS FOR PRODUCING QUINOLINECARBALDEHYDE
CN100378077C (zh) * 2002-11-06 2008-04-02 日产化学工业株式会社 喹啉甲醛类的制造方法
US7420059B2 (en) * 2003-11-20 2008-09-02 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
WO2005058834A2 (en) 2003-12-12 2005-06-30 Wyeth Quinolines useful in treating cardiovascular disease
KR20070042164A (ko) * 2004-07-05 2007-04-20 아스텔라스세이야쿠 가부시키가이샤 피라졸로피리딘 유도체
CN100445267C (zh) * 2005-10-21 2008-12-24 上海医药工业研究院 4-(4-氟-苯基)-3-羟甲基-2-环丙基-喹啉的制备方法
KR20150027267A (ko) 2012-06-29 2015-03-11 화이자 인코포레이티드 LRRK2 억제제로서의 4-(치환된-아미노)-7H-피롤로[2,3-d]피리미딘
CN103204807B (zh) * 2013-04-08 2015-12-23 黄河三角洲京博化工研究院有限公司 一种2-环丙基-4-（4-氟-苯基）-3-喹啉甲醛的合成方法
EP3081566B1 (en) * 2013-12-13 2018-03-07 Daiichi Sankyo Company, Limited 5-hydroxy-4-(trifluoromethyl)pyrazolopyridine derivative
WO2015092592A1 (en) 2013-12-17 2015-06-25 Pfizer Inc. Novel 3,4-disubstituted-1h-pyrrolo[2,3-b]pyridines and 4,5-disubstituted-7h-pyrrolo[2,3-c]pyridazines as lrrk2 inhibitors
CN104031034B (zh) * 2014-07-01 2017-01-04 上海信谊百路达药业有限公司 一种匹伐他汀钙原料药中间体的制备方法
MX2018003215A (es) 2015-09-14 2018-06-08 Pfizer Derivados de imidazo[4,5-c]quinolina e imidazo[4,5-c][1,5]naftirid ina novedosos como inhibidores de lrrk2.

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1336714C (en) * 1987-08-20 1995-08-15 Yoshihiro Fujikawa Quinoline type mevalonolactone inhibitors of cholesterol biosynthesis
JP2569746B2 (ja) * 1987-08-20 1997-01-08 日産化学工業株式会社 キノリン系メバロノラクトン類
US4761419A (en) * 1987-12-07 1988-08-02 Warner-Lambert Company 6-(((substituted)quinolinyl)ethyl)-and ethenyl)tetrahydro-4-hydroxypyran-2-one inhibitors of cholesterol biosynthesis
US4822799A (en) * 1988-01-27 1989-04-18 Sandoz Pharm. Corp. Pyrazolopyridine analogs of mevalonolactone and derivatives thereof useful for inhibiting cholesterol biosynthesis in mammals
JP2890448B2 (ja) * 1988-04-26 1999-05-17 日産化学工業株式会社 ピラゾロピリジン系メバロノラクトン類
US5024999A (en) * 1988-04-26 1991-06-18 Nissan Chemical Industries Ltd. Pyrazolopyridine type mevalonolactones useful as pharmaeuticals
US5026698A (en) * 1988-11-02 1991-06-25 Nissan Chemical Industries, Ltd. Thienopyridine type mevalonolactones

Also Published As

Publication number Publication date
CZ302792A3 (en) 1993-10-13
KR100264543B1 (ko) 2001-10-24
CA2079706C (en) 2004-03-30
HU214624B (hu) 1998-04-28
AU2601292A (en) 1993-04-08
UA39095C2 (uk) 2001-06-15
JP3130342B2 (ja) 2001-01-31
NZ244555A (en) 2000-06-23
CZ281786B6 (cs) 1997-01-15
DE69232217T2 (de) 2002-05-23
SK302792A3 (en) 1995-11-08
US6162798A (en) 2000-12-19
AU652669B2 (en) 1994-09-01
HUT62794A (en) 1993-06-28
TW238300B (no) 1995-01-11
DK0535548T3 (da) 2002-05-13
DE69232217D1 (de) 2002-01-03
EP0535548B1 (en) 2001-11-21
JPH06329540A (ja) 1994-11-29
RU2114620C1 (ru) 1998-07-10
SK279277B6 (sk) 1998-09-09
NO302452B1 (no) 1998-03-09
KR930007449A (ko) 1993-05-20
MX9205659A (es) 1993-04-01
CA2079706A1 (en) 1993-04-15
EP0535548A1 (en) 1993-04-07
ATE209035T1 (de) 2001-12-15
NO923858D0 (no) 1992-10-02

Similar Documents

Publication Publication Date Title
NO923858D0 (no) Inhibitor for aterosklerose-intimalfortykning
ATE114645T1 (de) Mevalonolaktone vom chinolin-typ.
GB9101660D0 (en) New compositions of matter
FI951731A (fi) Heterosykliset yhdisteet, joilla on sokeritautia vastustava vaikutus, niiden valmistus ja käyttö
BR8305546A (pt) Processo para a preparacao de derivados substituidos de 1-hidroxietil-triazolilo, composicoes de protecao as plantas e fungicidas e processos para o combate a fungos, para a protecao de plantas e para a preparacao de composicoes
EP1485377B8 (en) Pyranones useful as atm inhibitors
NZ331123A (en) 2-(benzo-1,4-oxathiin)- or (benzo-1,4-dithiin)-cyclohexane-1,3-diones and herbicidal compositions
FI943508A0 (fi) Pyridiinikarboksimidamidiyhdisteet ja niiden käyttö
ES8304579A1 (es) Un procedimiento para la preparacion de orto (sulfonil) oxibenceno-sulfonamidas.
DE69018335D1 (de) Imidazochinolonderivate.
ATE147376T1 (de) Heterocyclische derivate
GB9324871D0 (en) Novel compounds
FI853907A0 (fi) Mellanprodukter foer framstaellning av 16-fenoxi- och 16-substituerade fenoxi-prostatriensyraderivat.
GB2004885A (en) Indolopyrones
AU4776399A (en) Benflumetol derivatives, intermediates thereof and their use against parasiticalprotozoa and trematodes
JPS57142915A (en) Antiphlogistic agent
MX9303490A (es) Proceso para preaparar (1'r.3s 4r) 4-aciltio-azetidinonas.
ES2100998T3 (es) Composiciones farmaceuticas que contienen derivados de triazol para administracion rectal.
ES2038672T3 (es) Antagonistas h1 purinicos de la histamina, su preparacion y composiciones farmaceuticas que los contienen.
BR8704391A (pt) Composto,processo para sua preparacao,composicao herbicida e processo para combater o crescimento de planta indesejada

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees